Key result
Cardiometabolic comorbidities drive atrial cardiomyopathy primarily through progressive atrial fibrosis and remodeling.
Why the study?
A better understanding of the mechanisms of atrial remodeling and clinical correlations of atrial cardiomyopathy with AF and cardiometabolic comorbidities is needed to improve diagnosis, prognosis, and therapeutic approaches.
A better understanding of the mechanisms behind atrial cardiomyopathy and its correlations with cardiometabolic comorbidities is essential for improving diagnosis, prognosis, and therapeutic approaches.
Atrial cardiomyopathy (ACM) represents a constantly evolving concept, with increasing importance in contemporary research and clinical practice. A better understanding of the mechanisms involved in atrial remodeling and its clinical correlations especially with atrial fibrillation (AF) and other cardiometabolic comorbidities may induce a significant impact on the diagnosis, prognosis, and therapeutic approach of ACM-related comorbidities. Although initially described several decades ago, investigators have only recently highlighted that several renal, metabolic, and cardiovascular diseases are determining factors for atrial remodeling and subsequent ACM. Based on data from multiple recent studies, our research emphasizes the correlations between ACM and other coexisting pathologies including cardiovascular, respiratory, or metabolic diseases, with fibrosis being the most incriminated pathophysiological mechanism. In addition to the usual tests, the paraclinical assessment of ACM is increasingly based on the use of various cardiac biomarkers, while the cardiac magnetic resonance (CMR) has become an increasingly tempting diagnostic too for describing morphofunctional aspects of the heart chambers, with the gadolinium contrast enhanced CMR (LGE-CMR) emerging as a commonly used technique aiming to identify and quantify the precise extent of atrial fibrosis. Further research should be conducted in order to clarify our knowledge regarding atrial remodeling and, therefore, to develop new and improved therapeutic approaches in these patients.
No takes yet. Share an insight, caveat, or question.
Dmour et al. (2021) conducted a review in Atrial cardiomyopathy. Atrial cardiomyopathy mechanisms and management was evaluated. Atrial cardiomyopathy is driven by structural, electrical, and functional remodeling linked to cardiometabolic comorbidities, with fibrosis being the primary pathophysiological mechanism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: